Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 6:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–5 of 5 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Advanced Adult Hepatocellular Carcinoma, BCLC Stage B Adult Hepatocellular Carcinoma, BCLC Stage C Adult Hepatocellular Carcinoma
Interventions
Chinese herbal formulation PHY906, sorafenib tosylate, laboratory biomarker analysis, pharmacological study
Dietary Supplement · Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced May 21, 2026, 6:33 PM EDT
Conditions
Adult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma, BCLC Stage C Adult Hepatocellular Carcinoma, BCLC Stage D Adult Hepatocellular Carcinoma, Hilar Cholangiocarcinoma, Localized Non-Resectable Adult Liver Carcinoma, Recurrent Adult Liver Carcinoma, Recurrent Childhood Liver Cancer, Recurrent Extrahepatic Bile Duct Carcinoma, Recurrent Gallbladder Carcinoma, Stage II Gallbladder Cancer, Stage III Childhood Hepatocellular Carcinoma, Stage IIIA Gallbladder Cancer, Stage IIIB Gallbladder Cancer, Stage IV Childhood Hepatocellular Carcinoma, Stage IV Distal Bile Duct Cancer, Stage IVA Gallbladder Cancer, Stage IVB Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Carcinoma
Interventions
Capecitabine, Fluorouracil, Laboratory Biomarker Analysis, Leucovorin Calcium, Trametinib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
295
States / cities
Anchorage, Alaska • Anaheim, California • Auburn, California + 189 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced May 21, 2026, 6:33 PM EDT
Conditions
Advanced Adult Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Recurrent Adult Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v7, Stage IIIA Hepatocellular Carcinoma AJCC v7, Stage IIIB Hepatocellular Carcinoma AJCC v7, Stage IIIC Hepatocellular Carcinoma AJCC v7, Stage IV Hepatocellular Carcinoma AJCC v7, Stage IVA Hepatocellular Carcinoma AJCC v7, Stage IVB Hepatocellular Carcinoma AJCC v7, Unresectable Hepatocellular Carcinoma
Interventions
Laboratory Biomarker Analysis, Quality-of-Life Assessment, Sorafenib, Sorafenib Tosylate, Yttrium Y 90 Glass Microspheres
Other · Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced May 21, 2026, 6:33 PM EDT
Conditions
Advanced Hepatocellular Carcinoma
Interventions
Sorafenib+YIV-906, Sorafenib+placebo
Drug
Lead sponsor
Yiviva Inc.
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Flushing, New York • Lake Success, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2025 · Synced May 21, 2026, 6:33 PM EDT
Conditions
Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, BCLC Stage 0 Adult Hepatocellular Carcinoma, BCLC Stage A Adult Hepatocellular Carcinoma, BCLC Stage B Adult Hepatocellular Carcinoma, BCLC Stage C Adult Hepatocellular Carcinoma, BCLC Stage D Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma, Localized Resectable Adult Liver Carcinoma
Interventions
Gadoxetate Disodium, Magnetic Resonance Imaging
Drug · Device
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 18, 2015 · Synced May 21, 2026, 6:33 PM EDT